Supplementary Figures 1-3 The protein tyrosine-phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis Kathleen Spring 1# , Patrick Fournier 1# , Line Lapointe 1 , Catherine Chabot 1 , Jacinthe Roussy 1 , Sandra Pommey 1 , John Stagg 1, 2 , and Isabelle Royal 1, 3
By tabDorsal administration of 1% DNCB. Oral / Dorsal administration of C6. 8. 3. 7. Week s 0. 1. 5. 6. 2. 4. Dorsal administration of 0.3% DNCB. Supplementary figure 1.
By misuSupplementary Figure 1. A. rate of PDPN expression. CAF4: PDPN. 13.48%. 14.38%. CAF1. Time of trypsin/EDTA treatment (min). B. Cultured CAFs. CTRL. 2min. 13.87%. CAF2. CAF3. CAF4. CAF1. CAF3. CAF4. CAF2. Harvested CAFs. 5min. 10min. CAF1. CAF3. CAF4. CAF2. C.
By infinityclones. mass cultures. BMhTERT-1. BMhTERT-2. BM2A2. BM2B8. BM2A7. BM2A11. BM2B2. BM2A6. BM2A10. BM10A3. BM2A9. BM10B1. BM2B12. BMEC. p16 INK4a + + + + - + + + + + + + - - - -. kDa. 23. GSTPi. 42. Actin.
By nevapolyI:C. CpG. LPS. 0.32. 2.35. 0.92. 3.04. 0.83. 2.09. SSC. 95. 2.36. 92.8. 3.22. 95.2. 1.89. untreated. 0.65. 2.69. PI. 95.1. 1.56. A. polyI:C. CpG. LPS. untreated. 72.7. 66.1. 65.8. 69.6. FSC. B. Annexin V. Supplementary Figure 1
By teddySupplementary Figure 1. frt. F3. frt. F3. lx5171. lxP. lxP. lx5171. E1. OPE. OPE. OPE. OPE. OPE. OPE. E2. pA. SA. b geo. pA. inversion at F3 sites. inversion at frt sites. E1. E2. pA. OPE. OPE. OPE. OPE. OPE. OPE. SA. b geo. pA. Inversion by FLP. E1. OPE. OPE.
By tyneSupplementary figure 1. Viable. Viable. Apoptotic. Apoptotic. Necrotic. Necrotic. 120. SKOV-3. 100. 80. 60. % total number of cells. 40. 20. 0. 0 hr. 24 hr. 48 hr. 72 hr. 96 hr. - 22 kDa. WB:. - 15 kDa. α Bid α G3PDH. - 37 kDa. Caov-4. SKOV-3. A. 120. Caov-4. 100.
By ellaNephrin. Nephrin. Nephrin. Nephrin. Nephrin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. Synaptopodin. A. Merge. Merge. Merge. Merge. Merge. B. Podocin. Podocin. Podocin. Podocin. Podocin. Day 28. Control. Day 3. Day 15. Day 7. ADRN 11 mg/kg. Cont. Day3.
By lesSupplementary Figure 1. HUVEC. A549. ACHN. DU145. kDa. - 150. NRP1. - 102. - 150. NRP2. - 102. - 225. VEGFR-1. - 150. - 225. VEGFR-2. - 150. - 38. GAPDH. - 31. NRP1. GAPDH. Supplementary Figure 2. C. siRNA. C. #4914. #4820. kDa. - 150. - 102. - 38. - 31.
By tirzaOverlay. 7AAD. Myosin heavy chain. S3RNAi treated. Controls. Supplementary figure 1. myosin heavy chain protein levels ( reen ) in S3RNAi treated C2C12 cells is decreased in comparison to controls after 72 h in DM. Nuclei were counter-stained with 7-AAD (red).
By cullenSupplementary Figure 1. Heat map using Ingenuity Analysis s oftware and the “Cell Signaling” category. The range of difference b etween DU145 and DU145LN4 groups are 1.8-16.4 fold. relative. min. max.
By dympnaSupplementary Figure 1. A. B. C. D. E. A: 0. B: 1+. C: 2+. D: 3+. E: Normal bronchial epithelium. Supplementary Table 1. Summary of Tumors with Intrinsic Resistance.
By dougalSupplementary Figure 1. Kantidakis and White. 400ng. 200ng. 100ng. RNA:. Dr1 mRNA. 5S rRNA. pre-tRNA LEU. pre-tRNA TYR. tRNA Met. Alu RNA. 7SL RNA. U6 snRNA. ARPP P0 mRNA. Repression of tRNA genes by Dr1. Supplementary Figure 2. Kantidakis and White. A. Dr1 RNAi. control.
By jalenaSupplementary Figure 1. ATI-like. ATII. AMs. PBDMs. A. b. a. c. d. Control (MAAII) Sialidase (MAAII) Buffer (MAAII). e. f. g. h. i. j. k. l. Supplementary Figure 1. ATI-like. ATII. AMs. PBDMs. B. b. a. c. d. Control (SNA) Sialidase (SNA) Buffer (SNA). e. f.
By nitaraSupplementary Figure 1. A. MIG (pMSCV-ires-GFP). I. GFP. LTR. LTR. MIG-PL2 (pMSCV-PLAGL2-ires-GFP). PL2. GFP. LTR. LTR. I. B. CBFb-MYH11 + HPs. GFP sort. Gene expression profile. Genes commonly deregulated in PL2+ cells. MIG-PL2 transduction. MIG transduction. GFP sort.
By andieView Supplementary figure 1 PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Supplementary figure 1 PowerPoint presentations. You can view or download Supplementary figure 1 presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.